GlassScriptPhysician profile
Michelle N Lyons
NPI 1174724397
$396.85
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $51.64 · 2022: $18.37.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $94.66 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $65.71 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $58.71 | 2019 | |
| Daiichi Sankyo INC. | $38.19 | 2019 | |
| Therapeuticsmd, INC. | $36.58 | 2019 | |
| Pfizer INC. | $29.04 | 2019 | |
| Duchesnay USA Incorporated | $24.18 | 2019 | |
| Millicent US INC | $18.23 | 2020 | |
| Mission Pharmacal Company | $16.42 | 2019 | |
| Smith+Nephew, INC. | $15.13 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.